Canada's National Pharmacare Program Bad News For Pharma?
Big changes to Canada's pharmaceutical market could be afoot as the country starts to look at what a National Pharmacare program might look like. Moves to improve access to medicines could mean the demise of private drug plans, which would be bad news for companies.
You may also be interested in...
Hotly awaited recommendations on implementing a national pharmacare program in Canada have been published. The report also suggests how to improve Canada’s pricing and reimbursement process.
Health authorities in Ontario, Canada, have become the first to offer a universal drug program offering younger patients access to free medicines. The move could be a small step towards eventually establishing a National Pharmacare Program across Canada.
An agreement between Vertex and NHS England secures rapid access to Kaftrio, the company’s triple therapy for cystic fibrosis, including for patients with rare mutations not covered by the soon-to-be-granted European marketing authorization. The final price will depend on an assessment by health technology appraisal body NICE.